|
Latest Reports
|
| Date |
Description |
Country |
Analyst |
Download |
|
|
| 15-Feb-2024 |
IPCA Laboratories - Unichem integration weighs on margins; Maintain SELL with TP Rs 910 |
India |
Surya Patra |
 |
| 15-Nov-2023 |
IPCA Laboratories - Unichem integration dilutes earnings despite synergies; Re-iterate SELL with TP Rs 790 |
India |
Surya Patra |
|
| 13-Aug-2023 |
IPCA Laboratories - Below expected guidance; Unichem acquisition to dilute EPS; Downgrade to SELL with TP Rs 740 |
India |
Surya Patra |
|
| 26-Apr-2023 |
IPCA Laboratories - Unichem acquisition will not be EPS accretive till FY25: Maintain Neutral with lower TP Rs 800 |
India |
Surya Patra |
|
| 17-Feb-2023 |
IPCA Laboratories - Hurt by cost pressure; Expects margin recovery in FY24; Maintain Neutral with TP Rs 880 |
India |
Surya Patra |
|
| 15-Nov-2022 |
IPCA Laboratories- Cost pressure continues to hurt in the near term: Maintain NEUTRAL with TP Rs 820 |
India |
Surya Patra |
|
| 12-Aug-2022 |
IPCA Laboratories - Mounting cost pressure hurts FY23 earnings: Maintain Neutral with lowered TP of Rs 870 |
India |
Surya Patra |
|
| 26-May-2022 |
IPCA Laboratories -Cost pressure and trade challenges hurts FY23 earnings: Downgrade to NUETRAL with lowered TP Rs 1000 |
India |
Surya Patra |
|
| 15-Feb-2022 |
IPCA Laboratories - Dewas plant commissioning to offer integration advantage; Maintain BUY with TP Rs 1250 |
India |
Surya Patra |
|
| 17-Nov-2021 |
IPCA Laboratories - Integration led value growth visibility intact; Maintain BUY with TP Rs 2550 |
India |
Surya Patra |
|
| 06-Aug-2021 |
IPCA Laboratories - Long term value growth visibility intact: BUY with TP Rs 2500 |
India |
Surya Patra |
|
| 09-Nov-2020 |
IPCA Laboratories - All set for multi-year value growth; BUY with raised TP Rs 2650 |
India |
Surya Patra |
|
| 12-Aug-2020 |
IPCA Laboratories - All set for multi-year value growth; Buy with raised TP of 2360 |
India |
Surya Patra |
|
| 13-Feb-2020 |
IPCA Laboratories - Holds strong visibility for profitable growth |
India |
Surya Patra |
|
| 11-Nov-2019 |
IPCA Laboratories - Set for re-rating led by improving earning quality: Maintain BUY with raised TP Rs 1320 |
India |
Surya Patra |
|
| 14-Aug-2019 |
IPCA Labs (IPCA IN) - Secured by its strong domestic branded business; Upgrade to BUY with TP Rs 1080 |
India |
Surya Patra |
|
| 31-May-2019 |
IPCA Labs (IPCA IN) - Strong earnings visibility but priced-in; NEUTRAL with TP Rs 980 |
India |
Surya Patra |
|
| 13-Feb-2019 |
IPCA Labs (IPCA IN) - Set to achieve profitable growth; Upgrade to BUY with TP of Rs 940: |
India |
Surya Patra |
|
| 16-Nov-2018 |
IPCA Laboratories (IPCA IN) - On track to see progress in non-US business; NEUTRAL with TP Rs 730: |
India |
Surya Patra |
|
| 12-Aug-2018 |
IPCA Laboratories - Looking for sequential operating progress: Neutral with TP of Rs 680 |
India |
Surya Patra |
|
| 01-Jun-2018 |
IPCA Laboratories - Set for operational improvement despite plant issues |
India |
Surya Patra |
|
| 09-Feb-2018 |
IPCA Laboratories - See value progress in non-US business; NEUTRAL with TP of Rs 630 |
India |
Surya Patra |
|
| 01-Jun-2017 |
IPCA Laboratories (IPCA IN) - No visibility of plant clearance yet; Maintain NEUTRAL with TP of Rs 480 |
India |
Surya Patra |
|
| 14-Feb-2017 |
IPCA Laboratories (IPCA IN) - Operational challenges loom over earnings; NEUTRAL with TP of Rs 550: |
India |
Surya Patra |
|
| 14-Feb-2017 |
IPCA Laboratories (IPCA IN) - Operational challenges loom over earnings; NEUTRAL with TP of Rs 550: |
India |
Surya Patra |
|
|
|